Compare · GENB vs NVO
GENB vs NVO
Side-by-side comparison of Generate Biomedicines Inc. (GENB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GENB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 111.8x GENB ($1.64B).
- Over the past year, GENB is down 0.7% and NVO is down 45.7% - GENB leads by 45.0 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for GENB).
- NVO has more recent analyst coverage (25 ratings vs 6 for GENB).
- Company
- Generate Biomedicines Inc.
- Novo Nordisk A/S
- Price
- $12.76-1.62%
- $41.01-4.51%
- Market cap
- $1.64B
- $183.15B
- 1M return
- -6.49%
- -10.44%
- 1Y return
- -0.70%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 1
- 8
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GENB
- Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.
- SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.
- Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Generate Biomedicines Inc.
- Generate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- H.C. Wainwright initiated coverage on Generate Biomedicines with a new price target
- Piper Sandler initiated coverage on Generate Biomedicines with a new price target
- Morgan Stanley initiated coverage on Generate Biomedicines with a new price target
- Cantor Fitzgerald initiated coverage on Generate Biomedicines
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care